Brazil Covid-19

Brazil receives Pfizer’s request for emergency use of Paxlovid

By RT Staff Reporters · February 17, 2022 · 1 min read

RIO DE JANEIRO, BRAZIL – The Brazilian Health Regulatory Agency (ANVISA) on Wednesday, February 16, received a request from U.S. pharmaceutical company Pfizer for the emergency use of Paxlovid, a drug to treat Covid-19, the regulator reported.

Paxlovid is currently in use in the United States, China, Canada, Japan, and European Union countries. The data presented by the laboratory that the drug can reduce hospitalization and deaths by up to 89% when administered early in the infection will now be reviewed by ANVISA.

One-stop reference

Company Intelligence

Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.

Browse the directory →

According to Pfizer, Paxlovid is able to reduce the risk of hospitalization and death in Covid-19 patients by up to 89%. (photo internet reproduction)

The deadline for the assessment of the request will be 30 days, and within 24 hours “the documents submitted will be reviewed to ensure that they are in compliance with the required information,” and the technical analysis of the antiviral drug for oral use will begin.

Brazil receives Pfizer’s request for emergency use of Paxlovid

Daily Brief

Related Articles

Brazil’s Record $4.5bn Tourism Month Was Paid For at the Pump

One in Six New Cars Sold in Brazil Is Now Electrified

Brazil’s Oil Export Tax Died in Congress. It Was Back the Same Day

Brazil Debates Its Next Pension Reform as the Last One Unravels

Rotate for Best Experience

You've reached your free article limit